Stocktoria
Immunovant, Inc. IMVT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-14
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Financials | |||||
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M |
| Operating cash flow | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M |
| Shareholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M |
| Ratios | |||||
| Return on assets | -52.8% | -53.3% | -38.9% | -52.0% | -30.4% |
| Return on equity | -59.3% | -58.5% | -42.0% | -58.2% | -33.4% |
| Current ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 192,500 | $4.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001764013 · as of 2026-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.